Fundraising Fox
Neutrolis
Cambridge, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Neutrolis
Sign up to find every way you can get introduced to Neutrolis
- Your email: who you already know at Neutrolis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Neutrolis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Neutrolis is a clinical-stage biotech developing first-in-class therapies that degrade neutrophil extracellular traps (NETs) to address the root cause of autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis. Its approach targets the process of NETosis to treat these disorders without relying on immunosuppression.
Founders & leadership
Neutrolis was founded in 2017 by Abdul Hakkim Rahamathullah.
AH
Abdul Hakkim RahamathullahFounder
TF
Toby FoxNamed on SEC filing
Board
GC
Gerald ChanBoard director
AA
Anthony AiudiBoard director
JS
John SundyBoard director
Investors · 1
Prefix Capitallisted by Prefix CapitalSan Francisco
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$27.6M disclosed across 3 rounds · 2021–2025
▶$3.5MraisedJul 2025 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJul 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SundyDirector
- Gerald ChanDirector
- Anthony AiudiDirector, Executive Officer, Promoter
- Toby FoxDirector, Executive Officer, Promoter
- Abdul Hakkim RahamathullahDirector, Executive Officer, Promoter
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$965KraisedApr 2025 · 9 investors · BiotechnologyRule 506(b)
▶$965KraisedApr 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SundyDirector
- Abdul Hakkim RahamathullahDirector, Executive Officer, Promoter
- Toby FoxDirector, Executive Officer, Promoter
- Gerald ChanDirector
- Anthony AiudiDirector
- Offering amount
- $1M
- Amount sold
- $965K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.1MraisedDec 2021 · 28 investors · BiotechnologyRule 506(b)
▶$23.1MraisedDec 2021 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald ChanDirector
- Toby FoxExecutive Officer, Director, Promoter
- Abdul Hakkim RahamathullahExecutive Officer, Director, Promoter
- Anthony AiudiDirector
- Offering amount
- $40.6M
- Amount sold
- $23.1M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
NeurelisNeurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy. It also maintains a proprietary drug delivery and stabilization technology portfolio applicable to proteins, peptides, and small and large molecules.
Nurix TherapeuticsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
QuralisQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Parabilis MedicinesHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
Companies working in the same space as Neutrolis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $251.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $209.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Neutrolis do?
- Neutrolis is a clinical-stage biotech developing first-in-class therapies that degrade neutrophil extracellular traps (NETs) to address the root cause of autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis. Its approach targets the process of NETosis to treat these disorders without relying on immunosuppression.
- Who founded Neutrolis?
- Neutrolis was founded by Abdul Hakkim Rahamathullah in 2017.
- Who are Neutrolis's investors?
- Neutrolis's investors include Prefix Capital.
- How much funding has Neutrolis raised?
- Neutrolis has disclosed $27.6M raised across 3 rounds.
- Where is Neutrolis headquartered?
- Neutrolis is headquartered in Cambridge, US.